CATX
Income statement / Annual
Last year (2022), Perspective Therapeutics, Inc.'s total revenue was $7.10 M,
a decrease of 34.19% from the previous year.
In 2022, Perspective Therapeutics, Inc.'s net income was -$14.67 M.
See Perspective Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
06/30/2014 |
| Operating Revenue |
$7.10 M
|
$10.80 M
|
$10.05 M
|
$9.68 M
|
$7.31 M
|
$5.92 M
|
$4.76 M
|
$4.77 M
|
$4.61 M
|
$4.22 M
|
| Cost of Revenue |
$5.47 M |
$6.18 M |
$4.93 M |
$4.56 M |
$4.27 M |
$4.08 M |
$3.92 M |
$4.64 M |
$4.44 M |
$4.42 M |
| Gross Profit |
$1.63 M |
$4.62 M |
$5.12 M |
$5.12 M |
$3.05 M |
$1.84 M |
$838,000.00 |
$129,154.00 |
$167,393.00 |
-$196,471.00 |
| Gross Profit Ratio |
0.23 |
0.43 |
0.51 |
0.53 |
0.42 |
0.31 |
0.18 |
0.03 |
0.04 |
-0.05 |
| Research and Development
Expenses |
$2.60 M
|
$2.58 M
|
$1.43 M
|
$1.13 M
|
$1.47 M
|
$1.75 M
|
$965,000.00
|
$528,049.00
|
$614,771.00
|
$668,803.00
|
| General & Administrative
Expenses |
$10.87 M
|
$6.62 M
|
$4.69 M
|
$4.57 M
|
$4.17 M
|
$4.17 M
|
$3.92 M
|
$3.79 M
|
$2.40 M
|
$2.49 M
|
| Selling & Marketing
Expenses |
$3.23 M
|
$2.80 M
|
$2.44 M
|
$2.98 M
|
$2.68 M
|
$2.66 M
|
$2.31 M
|
$1.35 M
|
$1.49 M
|
$1.23 M
|
| Selling, General &
Administrative Expenses |
$14.21 M
|
$9.43 M
|
$7.13 M
|
$7.55 M
|
$6.85 M
|
$6.83 M
|
$6.23 M
|
$5.14 M
|
$3.89 M
|
$3.72 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
-$73,000.00 |
$2,000.00 |
$0.00 |
-$48,000.00 |
-$456,284.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$17.43 M |
$12.01 M |
$8.56 M |
$8.60 M |
$8.33 M |
$8.57 M |
$7.15 M |
$5.21 M |
$4.50 M |
$4.39 M |
| Cost And Expenses |
$22.90 M |
$18.19 M |
$13.49 M |
$13.16 M |
$12.59 M |
$12.65 M |
$11.07 M |
$9.85 M |
$8.94 M |
$8.81 M |
| Interest Income |
$1.12 M |
$119,000.00 |
$59,000.00 |
$30,000.00 |
$108,000.00 |
$29,000.00 |
$118,000.00 |
$218,145.00 |
$282,745.00 |
$12,113.00 |
| Interest Expense |
$0.00 |
$119,000.00 |
$0.00 |
$0.00 |
$0.00 |
-$29,000.00 |
-$145,000.00 |
$950.00 |
$2,214.00 |
$883.00 |
| Depreciation &
Amortization |
$344,000.00
|
$248,000.00
|
$9,000.00
|
$147,000.00
|
-$24,000.00
|
$80,000.00
|
$68,000.00
|
$470,851.00
|
$576,380.00
|
$685,396.00
|
| EBITDA |
-$14.84 M
|
-$7.39 M
|
-$3.43 M
|
-$3.48 M
|
-$5.30 M
|
-$6.70 M
|
-$6.19 M
|
-$4.39 M
|
-$4.05 M
|
-$3.89 M
|
| EBITDA Ratio |
-2.09 |
-0.68 |
-0.34 |
-0.36 |
-0.72 |
-1.13 |
-1.3 |
-0.92 |
-0.88 |
-0.92 |
| Operating Income Ratio
|
-2.14
|
-0.68
|
-0.34
|
-0.36
|
-0.72
|
-1.14
|
-1.32
|
-1.07
|
-0.94
|
-1.09
|
| Total Other
Income/Expenses Net |
$512,000.00
|
$119,000.00
|
$50,000.00
|
$30,000.00
|
$134,000.00
|
$29,000.00
|
$27,000.00
|
$154,000.00
|
$374,605.00
|
-$1.38 M
|
| Income Before Tax |
-$14.67 M |
-$7.27 M |
-$3.39 M |
-$3.45 M |
-$5.14 M |
-$6.70 M |
-$6.16 M |
-$4.71 M |
-$3.68 M |
-$5.96 M |
| Income Before Tax Ratio
|
-2.07
|
-0.67
|
-0.34
|
-0.36
|
-0.7
|
-1.13
|
-1.29
|
-0.99
|
-0.8
|
-1.41
|
| Income Tax Expense |
$0.00 |
-$119,000.00 |
-$199,000.00 |
-$177,000.00 |
-$294,000.00 |
-$29,000.00 |
-$145,000.00 |
-$371,195.00 |
-$655,136.00 |
$1.37 M |
| Net Income |
-$14.67 M |
-$7.15 M |
-$3.19 M |
-$3.27 M |
-$4.85 M |
-$6.70 M |
-$6.16 M |
-$4.71 M |
-$3.68 M |
-$5.96 M |
| Net Income Ratio |
-2.07 |
-0.66 |
-0.32 |
-0.34 |
-0.66 |
-1.13 |
-1.29 |
-0.99 |
-0.8 |
-1.41 |
| EPS |
-0.1 |
-0.0504 |
-0.0307 |
-0.0484 |
-0.0723 |
-0.12 |
-0.11 |
-0.0856 |
-0.0671 |
-0.14 |
| EPS Diluted |
-0.1 |
-0.0504 |
-0.0307 |
-0.0484 |
-0.0723 |
-0.12 |
-0.11 |
-0.0856 |
-0.0671 |
-0.14 |
| Weighted Average Shares
Out |
$142.10 M
|
$141.99 M
|
$103.84 M
|
$67.60 M
|
$67.04 M
|
$55.16 M
|
$55.02 M
|
$55.01 M
|
$54.88 M
|
$42.68 M
|
| Weighted Average Shares
Out Diluted |
$142.10 M
|
$141.99 M
|
$103.84 M
|
$67.60 M
|
$67.04 M
|
$55.16 M
|
$55.02 M
|
$55.02 M
|
$54.88 M
|
$42.68 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
